Stock of the Week: CSL and the defensive growth trade

CSL's plasma collection trajectory continues to improve, supporting margin recovery across key therapies. The company's balance sheet strength allows continued investment in R&D and manufacturing scale.

While competitive dynamics in plasma are evolving, CSL's global footprint and proven execution provide confidence in mid-cycle earnings resilience.

Investors will watch upcoming regulatory filings and pipeline updates for signals on next leg growth.